GlassScriptPhysician profile
Curtis Andrews
NPI 1265606735
$3,476.58
in general payments reported to CMS, 2019-2025
44 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $459 · 2021: $708 · 2022: $732 · 2023: $324 · 2024: $296 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.67 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $454.37 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $247.53 | 2019-2023 | Shingrix, Arexvy, Bexsero |
| Novo Nordisk INC | $232.91 | 2019-2025 | Ozempic |
| Janssen Pharmaceuticals, INC | $143.10 | 2019-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $139.39 | 2019-2025 | |
| Abbott Laboratories | $135.38 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $123.43 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $120.55 | 2019-2024 | Breztri |
| Pfizer INC. | $103.51 | 2019-2025 | |
| Boston Scientific Corporation | $101.84 | 2019-2022 | |
| Cranial Technologies, INC | $91.78 | 2019-2025 | Doc Band |
| Sunovion Pharmaceuticals INC. | $87.41 | 2019-2020 | |
| Vistapharm, INC. | $75.84 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.